LEROUX Pauline
Corbeil-Essonnes, France, 91106
NCT Number: NCT05152862
The aim of the study is to assess whether a delay of the first examination can be safely considered in French population. Secondary objectives are to describe retinopathy of prematurity (ROP) in a population of premature from two French tertiary NICU and to identify co-morbidities associated with the development of severe ROP.
Looking for future studies?
Notify Me0 year–31 week
All sexes
Observational
Corbeil-Essonnes, France, 91106
Retinopathy of prematurity (ROP) is a major cause of blindness and visual impairment in children worldwide. Despite a stable incidence over the last decades, improvements in neonatal care and survival of extremely premature lead to an increased screening and follow up of ROP. Retinal examination is painful and can result in clinical deterioration, it also generates significant health care costs. In this way, several studies suggest the need to optimize screening without ignoring severe ROP requiring treatment. Recently, SCREENROP in Canada and SWEDROP studies in Sweden contributed to a modification of the national screening guidelines with a reducing upper limit at 30 weeks of gestational age (GA) and a postponing of the first examination. Because of the population studied, those recommendations cannot be applicable in other countries.
Recommendations in France are to screen infants < 31 GA or 1250 g, first examination should be performed at PMA 31 in infants < 27 GA and at 4 weeks postnatal age (PNA) in infants born at 27 GA or more. Our main hypothesis is that a reduction of the screening criteria by decreasing the upper limit of the threshold at 30 GA and/or postponing the first examination is acceptable in a population of premature newborns from two French tertiary NICU. This simplification of the screening modalities could reduced the number of fundus examinations performed, while limiting risks for the patient as well as costs. This study could be a pilot study for a national multicenter trial, with the objective of revising national screening guidelines.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Retinal laser photocoagulation
Anti-VEGF intravitreous injection
Time frame: Day 0
Number
Time frame: Day 0
days
Time frame: Day 0
days
Time frame: Day 0
days
Centre Hospitalier Sud Francilien
Other
Evaluation of the Criteria and Modalities of Screening for Retinopathy of Prematurity in Two French Tertiary NICU : is a Simplification Possible ?
Acronym: DEREP3
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05133999
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Eye Diseases
Paris, France
View Trial DetailsNCT07016984
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Eye Diseases
Sariyer, İ̇stanbul, Turkey (Türkiye)
View Trial DetailsNCT00895869
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Eye Diseases
Edinburgh, United Kingdom
View Trial DetailsNCT03650621
Acupuncture, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Sydney, New South Wales, Australia
View Trial Details